• Explore /
  • Poster
  • / Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.

Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.

Abstract Poster

Authors

null

Pei Dong

Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

Pei Dong , Wensu Wei , Lijuan Jiang , Zhiling Zhang , Deling Wang , Yulu Peng , Tingxuan Huang , Xi Zhong , Shengjie Guo , Hui Han , Xiuyu Cai , Fangjian Zhou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT05220267

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4544)

DOI

10.1200/JCO.2024.42.16_suppl.4544

Abstract #

4544

Poster Bd #

239

Abstract Disclosures

Similar Posters

First Author: Qin Xu

First Author: Ning Li

First Author: Xiuli Yang

First Author: Yonggui Hong